HTG Molecular Diagnostics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HTGMQ research report →
About the company
HTG Molecular Diagnostics, Inc. operates as a life sciences company, specializing in the realm of precision medicine. They furnish specialized instruments, consumable products, and software applications engineered to automate the processing of samples and characterize a variety of molecular targets.
- CEO
- John L. Lubniewski
- IPO
- 2015
- Employees
- 53
- HQ
- Tucson, AZ, US
Price Chart
- Market Cap
- $221
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- 28.18%
- Op Margin
- -327.19%
- Net Margin
- -339.20%
- ROE
- -273.49%
- ROIC
- -151.00%
- Revenue
- $6.37M · -28.52%
- Net Income
- $-21,594,476 · -25.95%
- EPS
- $-24.28 · 18.14%
- Op Income
- $-20,829,596
- FCF YoY
- -7.45%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.76
- Avg Volume
- 45
Get TickerSpark's AI analysis on HTGMQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HTGMQ coverage
Recent articles, reports, and earnings notes.
No research on HTGMQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HTGMQ report →Similar companies
Peers in the same neighborhood.